Opinion

Video

Key Highlights from EV-302 Study at ESMO 2023

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.

Daneshmand discusses results from the EV-302 phase 3 trial of enfortumab vedotin (EV) plus pembrolizumab (pembro) vs chemotherapy for first-line treatment of locally advanced or metastatic urothelial carcinoma. He notes that 10% to 20% of patients with bladder cancer present with metastatic disease, with up to 50% progressing post cystectomy. Cisplatin-based chemotherapy has been considered the standard of care for decades.

The EV-302 trial compared EV-pembro with chemotherapy (gemcitabine with cisplatin or carboplatin) in 886 patients. With median 17.2-month follow-up, EV-pembro significantly prolonged progression-free survival (12.5 vs 6.3 months; HR, 0.45) and overall survival (31.5 vs 16.1 months; HR, 0.47), reducing the risk of progression or death by 55% and 53%, respectively. Approximately one-third of patients had a prolonged response to EV-pembro.

Daneshmand believes these results are strong enough to change the standard of care for first-line treatment of advanced urothelial carcinoma to EV-pembro for both cisplatin-eligible and -ineligible patients. He expects rapid adoption of guidelines given the magnitude of benefit demonstrated.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Dr Carrie Kitko
Dr Ibrahim Aldoss
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo